Technology

VIMO Technology

The company’s VIMO technology consists of compounds that preferentially attack the mitochondria (energy powerhouses) of cancer cells to destroy them by two processes known as apoptosis and autophagy. Dying by autophagy results in the production  of cancer antigen-containing vesicles known as “autophagosomes”. These autophagosomes are taken up by immune cells known as dendritic cells, which process the cancer antigens and ”show” them to a unique population of immune cells known as T lymphocytes, which then are stimulated to recognize and destroy more cancer cells. 

Extensive proof-of-concept in vitro and in vivo studies have demonstrated anti-cancer activity of VIMO compounds against several tumor types. They include mouse and human triple negative breast, HER2+ breast, melanoma, lung, prostate, and ovarian cancer cells, as well as myeloma cell lines and children’s cancers including osteosarcoma and rhabdomyosarcoma cell lines.